Medication info
Tranta Duo Tablet 2.5/850 mg

Tranta Duo Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceuticals Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablets
Packaging
30 tablets/box [(6 tablets/PTP x 5 packs)]
Approval status
Active

MFDS item code 202400701 · Approved 2024.03.29 · Insurance code 649508460

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; it may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at the doses of linagliptin and metformin they were previously taking. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: An initial dose of this medicine consisting of linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose of metformin similar to the patient's current dose should be considered. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: An initial dose of this medicine consisting of linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose of metformin similar to the patient's current dose should be considered. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Contraindications).

Ingredients

Manufacturer
Unimed Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to enhance blood sugar control in patients with type 2 diabetes when combination therapy with linagliptin and metformin is appropriate, alongside dietary and exercise therapy.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; it may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at the doses of linagliptin and metformin they were previously taking. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: An initial dose of this medicine consisting of linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose of metformin similar to the patient's current dose should be considered. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: An initial dose of this medicine consisting of linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose of metformin similar to the patient's current dose should be considered. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution and appropriate monitoring are required. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Contraindications).

Precautions

This medication may rarely cause a serious side effect known as lactic acidosis, so caution is required. Do not administer this medication to patients who have allergies to any active or inactive ingredients, or to patients with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. It should not be used in patients with severely impaired kidney function, severe renal failure, acute myocardial infarction, shock, severe infections, or any condition that may affect kidney function. Patients with impaired liver function, severe gastrointestinal disorders, acute alcohol intoxication, and alcohol use disorder, as well as those in a state of nutritional deficiency, are advised not to use this medication. Pregnant or breastfeeding women should not use this medication, and those planning pregnancy should consult their physician. When taking this medication with sulfonylureas or insulin, the risk of hypoglycemia increases, so blood glucose should be carefully monitored. Regular kidney function testing is necessary to adjust the dosage appropriately, particularly in the elderly who are more prone to kidney function decline. If iodine contrast media is to be used during radiological examinations, this medication should be temporarily discontinued before and after the examination, and may be resumed only after kidney function stabilizes. In cases of acute surgery, this medication should be discontinued 48 hours prior, and resumed once kidney function has recovered post-surgery. If symptoms such as pancreatitis or bullous pemphigoid occur during treatment, consult a physician immediately and discontinue the medication if necessary. Long-term use may lead to vitamin B12 deficiency, so it is recommended to routinely check vitamin B12 levels. The risk of lactic acidosis may increase when this medication is taken with alcohol, thus alcohol consumption should be avoided. This medication may interact with other drugs, so it is advised to discuss any medications, especially those affecting kidney function, with healthcare professionals. Use in children under 10 years or adolescents is not recommended, and safety and efficacy in pediatric patients over 10 years have not been sufficiently established. There is insufficient research on the effects on driving or operating machinery, so caution is advised. In the case of overdose, gastrointestinal disturbances and lactic acidosis may occur, and immediate medical treatment should be sought if symptoms appear.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased vitamin B12 and deficiency
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 149 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • gastrointestinal disorders
  • irritable bowel syndrome
  • burning mouth syndrome
  • colitis
  • abdominal discomfort
  • dysphagia
  • gastric ulcer
  • gum bleeding
  • intestinal obstruction
  • tooth loss
  • hemorrhoids
  • lower abdominal pain
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • cerebral infarction
  • dysphonia
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastases
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • dizziness
  • kidney transplant failure
  • hyperglycemia
  • dyspnea
  • pruritus
  • insomnia
  • depression
  • hypertension
  • erectile dysfunction
  • goiter
  • anxiety
  • mood disorders
  • contusions
  • bone contusions
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hearing loss
  • benign prostatic hyperplasia
  • confusion state
  • nocturia
  • dermatitis
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • drowsiness
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • speech disorder
  • nosebleed
  • increased blood triglycerides
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • increased ALT
  • increased AST
  • male-pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • insomnia
  • depression
  • hypertension
  • dizziness
  • benign prostatic hyperplasia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to keep air and moisture out. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablets

Package unit

30 tablets/box [(6 tablets/PTP x 5 packs)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.